GeneVentiv Therapeutics, a gene therapy company, today announced it has signed a global licensing agreement with Duke ...

The raise will go toward trialing the company’s lead drug for phosphomannomutase-2 congenital disorder of glycosylation, a ...

The biotech is developing an experimental drug for the most common of a family of disorders all caused by errors in ...

Learn more about whether Amicus Therapeutics, Inc. or Moderna, Inc. is a better investment based on AAII's A+ Investor grades ...

Ian MacPherson has had to overcome more challenges in his lifetime than any person should ever have to endure. The Morpeth man has one more obstacle he’d like to clear – to get a job.

RFK Jr.'s Health Department shut down an advisory group that recommends how to test newborns for genetic disorders ...

Sanofi has added another string to its Pompe disease therapy bow, after getting FDA approval for Nexviazyme, its latest therapy for the rare, inherited disorder. The US regulator has approved ...

Dyne Therapeutics, Inc.’s DYN share price has surged by 6.89%, which has investors questioning if this is right time to sell.

At a time when America is facing unprecedented debt, with inflation hitting hardworking families and entitlement programs ...

Bengaluru: The medical education department is reaching out to corporate entities for support in treating children affected ...

Two other programs are for MZE782 in Chronic Kidney Disease and Phenylketonuria, both in phase 1 trials, and one partnered program, with Shionogi, called MZE001 and targeting Pompe Disease.

We recently published a list of 10 Best Low Priced Growth Stocks To Invest In. In this article, we are going to take a look ...